Lixte Biotechnology

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Lixte Biotechnology sent this email to their subscribers on June 6, 2024.

LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. has just released the following news:

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Click here to read the full article

If you have any questions, or would like to contact Investor Relations, please reply to this email.

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180, Pasadena, CA 91101 United States of America

https://www.lixte.com

To change your subscription preferences, please click here.

Text-only version of this email

LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. has just released the following news: SCIENTIFIC JOURNAL REPORTS FINDINGS THAT SHOW LIXTE’S LEAD CLINICAL COMPOUND, LB-100, INCREASES RECOGNITION OF COLON CANCER CELLS BY THE IMMUNE SYSTEM Click here to read the full article If you have any questions, or would like to contact Investor Relations, please reply to this email. LIXTE Biotechnology Holdings, Inc. 680 E Colorado Blvd., Suite 180, Pasadena, CA 91101 United States of America To change your subscription preferences, please click here.
Show all

The Latest Emails Sent By Lixte Biotechnology

More Emails, Deals & Coupons From Lixte Biotechnology

Email Offers, Discounts & Promos From Our Top Stores